Post by Concordia Healthcare M&A Coverage

Merck acquires Verona Pharma | $10Bn | Respiratory Swipe through Concordia's full deal coverage on one of the most strategically significant respiratory deals of 2025. A bolt-on and build acquisition — Merck acquired Verona Pharma to establish a commercial-stage entry point into respiratory through OHTUVAYRE (ensifentrine), the first novel inhaled COPD maintenance treatment mechanism in over two decades, directly addressing its strategic imperative to diversify beyond Keytruda. Financial Advisors Sell-Side Advisor: Centerview Partners Buy-Side Advisors: Citi Bank | Morgan Stanley Key Deal Highlights Total Deal Value: $10Bn | $107/ADS | All-cash transaction Funding: ~$6Bn debt issuance + ~$4Bn cash on hand Announced: July 2025 | Closed: October 2025 📎 Full coverage includes deal structure, funding stack, deal rationale, and Centerview's sell-side valuation methodology. #HealthcareMandA #Respiratory #COPD #Merck #VeronaPharma #Biopharma #DealCoverage #Merger #Acquisition #Finance #InvestmentBanking